You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

High%20Risk%20Multiple%20Myeloma

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Plasma Cell Myeloma Trial in Atlanta (Carfilzomib, Dexamethasone, Pomalidomide)

Recruiting
  • Plasma Cell Myeloma
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Oct 5, 2021

Multiple Myeloma Trial in Tianjin (anti-BCMA CAR-T)

Recruiting
  • Multiple Myeloma
  • anti-BCMA CAR-T
  • Tianjin, Tianjin, China
    Institute of Hematology and Blood Diseases Hospital Chinese Acad
May 4, 2023

Multiple Myeloma Trial in Guangzhou (Selinexor, Bortezomib, Lenalidomide)

Recruiting
  • Multiple Myeloma
  • Guangzhou, Guangdong, China
  • +3 more
Aug 16, 2022

Myeloma Trial in Houston (Belantamab mafodotin)

Recruiting
  • Myeloma
  • Belantamab mafodotin
  • Houston, Texas
    M D Anderson Cancer Center
Jul 9, 2022

Multiple Myeloma Trial in United States (Allogeneic HSCT, Fludarabine, Melphalan)

Completed
Has Results
  • Multiple Myeloma
  • Allogeneic HSCT
  • +5 more
  • Birmingham, Alabama
  • +14 more
Jan 25, 2022

Multiple Myeloma Trial in Shanghai (GC012F injection)

Recruiting
  • Multiple Myeloma
  • GC012F injection
  • Shanghai, Shanghai, China
    Shanghai Changzheng Hospital
Aug 1, 2022

Safety and Efficacy Trial in Suzhou (anti-CD19 and anti-BCMA CAR, Immunomodulatory drugs)

Recruiting
  • Safety and Efficacy
  • anti-CD19 and anti-BCMA CAR
  • Immunomodulatory drugs
  • Suzhou, Jiangsu, China
    First Affiliated Hospital, Soochow University
May 17, 2021

Newly Diagnosed Multiple Myeloma Trial in Germany (Isatuximab, Lenalidomide, Bortezomib)

Not yet recruiting
  • Newly Diagnosed Multiple Myeloma
  • Hamburg, Germany
  • +3 more
Dec 16, 2022

Smoldering Plasma Cell Myeloma Trial in Houston (Laboratory Biomarker Analysis, Pembrolizumab)

Active, not recruiting
Has Results
  • Smoldering Plasma Cell Myeloma
  • Laboratory Biomarker Analysis
  • Pembrolizumab
  • Houston, Texas
    M D Anderson Cancer Center
Mar 23, 2022

Developing Myeloma in a High-Risk Screened Population (PROMISE)

Recruiting
  • Multiple Myeloma
  • Sample of Blood
  • Baltimore, Maryland
  • +2 more
Mar 22, 2022

Multiple Myeloma Trial in Little Rock (Pomalidomide)

Completed
Has Results
  • Multiple Myeloma
  • Little Rock, Arkansas
    University of Arkansas for Medical Sciences, Myeloma Institute f
Mar 30, 2021

Autologous Hematopoietic Stem Cell Transplant Recipient, Loss of Chromosome 17p, Plasma Cell Leukemia Trial in Duarte (drug,

Active, not recruiting
  • Autologous Hematopoietic Stem Cell Transplant Recipient
  • +4 more
  • Duarte, California
    City of Hope
Mar 17, 2022

Smoldering Multiple Myeloma Trial in Boston (Nivolumab, Lenalidomide, Dexamethasone)

Suspended
  • Smoldering Multiple Myeloma
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Jan 4, 2022

High-risk Smoldering Multiple Myeloma, Multiple Myeloma Trial in Boston (Daratumumab, Bortezomib, Lenalidomide)

Recruiting
  • High-risk Smoldering Multiple Myeloma
  • Multiple Myeloma
  • Boston, Massachusetts
  • +1 more
Oct 18, 2021

Multiple Myeloma Trial in Shanghai (GC012F injection)

Unknown status
  • Multiple Myeloma
  • GC012F injection
  • Shanghai, Shanghai, China
    Shanghai Changzheng Hospital
Sep 21, 2021

Multiple Myeloma Trial in Austria, Germany, Israel (Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA], Placebo 1.7 ml

Active, not recruiting
  • Multiple Myeloma
  • Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
  • Placebo 1.7 ml Subcutaneous Solution
  • Graz, Austria
  • +9 more
Aug 24, 2022

Smoldering Multiple Myeloma Trial in United States (Carfilzomib, Lenalidomide, Daratumumab)

Active, not recruiting
  • Smoldering Multiple Myeloma
  • Tampa, Florida
  • +9 more
Jul 8, 2022

Monoclonal Gammopathy, Smoldering Multiple Myeloma Trial in United States (Daratumumab)

Active, not recruiting
  • Monoclonal Gammopathy
  • Smoldering Multiple Myeloma
  • Monterey, California
  • +5 more
Nov 1, 2021

Myeloma, Newly Diagnosed, High Risk Trial in GuangZhou (bortezomib, Lenalidomide, Dexamethasone)

Unknown status
  • Myeloma
  • +2 more
  • GuangZhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Dec 15, 2020

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in United States (drug, biological, other)

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Des Moines, Iowa
  • +8 more
Jan 12, 2023

Multiple Myeloma Trial in France (Carfilzomib, Daratumumab, Lenalidomide)

Active, not recruiting
  • Multiple Myeloma
  • Nantes, Pays De La Loire, France
  • +11 more
Apr 27, 2021

Smoldering Myeloma, Smoldering Multiple Myeloma Trial in United States (Elotuzumab, Lenalidomide, Dexamethasone)

Active, not recruiting
  • Smoldering Myeloma
  • Smoldering Multiple Myeloma
  • Denver, Colorado
  • +8 more
Nov 1, 2021

Multiple Myeloma Trial in Singapore (Carfilzomib, , Cyclophosphamide, Dexamethasone)

Completed
  • Multiple Myeloma
  • Carfilzomib, , Cyclophosphamide, Dexamethasone
  • Singapore, Singapore
  • +1 more
Oct 15, 2020

Plasma Cell Myeloma Trial in Atlanta (Belantamab Mafodotin, Dexamethasone, Pomalidomide)

Recruiting
  • Plasma Cell Myeloma
  • Belantamab Mafodotin
  • +2 more
  • Atlanta, Georgia
    Emory University/Winship Cancer Institute
Jul 21, 2022

Multiple Myeloma Trial in Little Rock (Velcade, Melphalan, Thalidomide)

Active, not recruiting
  • Multiple Myeloma
  • Little Rock, Arkansas
    University of Arkansas for Medical Sciences
Sep 7, 2021